What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly Eli Lilly's (LLY) Alzheimer's efforts are not central to our investment case, but Biogen's (BIIB) full trial data is incrementally positive.
from Top News and Analysis (pro)
via By Anand Gupta
from Top News and Analysis (pro)
via By Anand Gupta
Tags
Finance and Accounting Blogs
Financial Blogs
Mr. Anand Gupta
the anand gupta show
Top News and Analysis (pro)
What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly